ArticleJournal of pain research2026
An Integrated Multi-Tissue Single-Cell Transcriptomic Analysis Highlights the CCL2-CCR2 Signaling Pathway as a Potential Therapeutic Target in Neuropathic Pain.
Article in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuropathic pain involves complex neuroimmune interactions across the somatosensory nervous system, yet a comprehensive multi-tissue cellular landscape remains lacking. Methods: We integrated single-cell RNA sequencing data from the sciatic nerve (SN), dorsal root ganglion (DRG), and spinal cord (SC) of spared nerve injury (SNI) mice. The therapeutic potential of the selective CCR2 antagonist RS504393 was evaluated in vivo. Results: Macrophages dominated the injured SN (40.5%), exhibiting an inferred transcriptional shift from a resident-like Mrc1 Conclusion: This study provides an integrated multi-tissue single-cell analysis of neuropathic pain and highlights the CCL2-CCR2 signaling pathway as a potential non-opioid therapeutic target at the peripheral neuroimmune interface, with pharmacological evidence suggesting downstream central effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.